About Life Science Angels
Life Science Angels, established in 2004, is an angel investment group based in Sunnyvale, United States. It primarily focuses on Series A investments in companies in United States. Its portfolio includes 43 firms, spanning the Life Sciences, High Tech sectors. Its most notable investments include companies like Owlet, Quartzy and Mission Bio. As of Apr 2026, Life Science Angels has witnessed 11 portfolio exits. Its latest investment was a $3M Seed round in ATDev on Oct 16, 2025, which also saw participation from UpHonest Capital and Nick Karl Dobrzelecki.
To date, 111 investors have co-invested in Life Science Angels's portfolio companies, including prominent names like Tech Coast Angels.
Key Metrics
Founded Year
2004
Location
Sunnyvale, United States
Sectors of Investment
Stages of Investment
Series A, Seed & 2 more
Locations of Investment
Life Science Angels' List of Top Investments
Life Science Angels has a portfolio of 43 companies. Their most notable investments are in Zephyrus Biosciences and Verdezyne.Their portfolio spans across United States, Canada and Netherlands. They have invested in Life Sciences, High Tech, HealthTech and 6 other sectors, across stages such as Series A, Seed and 2 more. Here is the list of top investments by Life Science Angels:1. Owlet
Provider of wearable socks for baby monitoring. The smart socks helps to monitor the babys heart rate, respiration and the user can check in on baby through a mobile device, cam-streams audio and video of the baby to the smartphone, and band. The band is a pregnancy tracker solution which helps to track the babys wellness.
Key facts about Owlet
- Founded Year: 2013
- Location: Lehi (United States)
- Annual Revenue: $78.1M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $55M
- Employee Count: 211 as on Dec 31, 2022
- Investors: Eniac Ventures, Black River Ventures and 30 Others
- Latest Funding Round: Post IPO, Feb 17, 2023, $*****
- Highlight: Public
2. Quartzy
Provider of web-based platform for labs management. It is a cloud-based platform that allows laboratories to streamline their communications, manage inventory, and purchase what they need to hit their milestones faster.
Key facts about Quartzy
- Founded Year: 2009
- Location: Palo Alto (United States)
- Stage: Series C
- Total Funding till date: $56.9M
- Employee Count: 97 as on Dec 31, 2022
- Investors: A.Capital Ventures, Orthogonal Thinker and 20 Others
- Latest Funding Round: Series C, Apr 13, 2026, $*****
- Highlight: Editors' Pick
3. Mission Bio
Provider of a single-cell multi-omics platform for genotypic and phenotypic analysis. The company's proprietary Tapestri platform enables the simultaneous detection of analytes, including SNVs, CNVs, and proteins for the precise treatment of cancer. Also, it offers DNA & protein panels, and Pharma Assay Development (PAD) Services.
Key facts about Mission Bio
- Founded Year: 2014
- Location: San Francisco (United States)
- Stage: Series C
- Total Funding till date: $120M
- Employee Count: 85 as on Mar 31, 2026
- Investors: Cota Capital, Mayfield and 27 Others
- Latest Funding Round: Series C, Aug 05, 2025, $*****
- Highlight: Editors' Pick
4. Journey
Provider of mental heath engagement platform for employees. The platform offers a variety of tools and resources to help improve mental wellbeing, including live classes with expert teachers and a supportive community.
Key facts about Journey
- Founded Year: 2015
- Location: New York City (United States)
- Valuation: $*****
- Stage: Series A
- Total Funding till date: $15.2M
- Employee Count: 70 as on Jul 01, 2024
- Investors: J-Ventures, Akatsuki and 23 Others
- Latest Funding Round: Series A, Apr 08, 2025, $*****
- Highlight: Editors' Pick
5. Vaxart
Developer of therapeutic solutions for treating multiple infectious diseases. The proprietary delivery platform of the company can deliver recombinant vaccines, thus enabling vaxart to introduce oral versions of certain vaccines. The pipeline includes vaccines for seasonal influenza, norovirus, RSV, HSV-2, avian influenza vaccine, and ebola vaccine. It has also developed vaccines for the treatment of influenza.
Key facts about Vaxart
- Founded Year: 2004
- Location: San Francisco (United States)
- Annual Revenue: $3.8M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $58M
- Employee Count: 110 as on Dec 31, 2021
- Investors: Care Capital, Codon Capital and 8 Others
- Latest Funding Round: Series C, Jan 08, 2015, $*****
- Highlight: Public
Life Science Angels' Year-on-Year Investment Trends
Life Science Angels has invested in 43 companies over the last 20 years, with an average of 2 new investments annually in the last 10 years. In 2025, it made 2 investments. Its most recent first time investment was in ATDev and most recent follow-on round was in Astrocyte Pharmaceuticals.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 2 | 0 | 2 |
2024 | 4 | 0 | 4 |
2023 | 1 | 1 | 2 |
2022 | 2 | 0 | 2 |
2021 | 2 | 0 | 2 |
2020 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
2018 | 1 | 0 | 1 |
2017 | 1 | 0 | 1 |
Life Science Angels' Investments by Stage
Life Science Angels has made 23 investments in Series A stage with an average round size of $8.06M, 12 investments in Seed stage with an average round size of $2.72M, 4 investments in Series B stage with an average round size of $8.62M and 2 investments in Series D stage with an average round size of $17.8M.Stage of entry | No. of Investments |
|---|---|
Series A | 23 |
Seed | 12 |
Series B | 4 |
Series D | 2 |
Note: We have considered here, only first round of investments
Life Science Angels' Investments by Sector
Life Science Angels has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Sustainability Tech and Enterprise Applications. Notably, it has invested in 38 Tech companies, 33 Enterprise (B2B) companies, 15 Software companies and at least 12 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 34 |
High Tech | 12 |
HealthTech | 9 |
Sustainability Tech | 9 |
Enterprise Applications | 7 |
Others | 13 |
Note: We have considered here, only first round of investments
Life Science Angels' Investments by Geography
Life Science Angels has made most investments in United States (39), followed by Canada where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 39 |
Canada | 1 |
Netherlands | 1 |
Note: We have considered here, only first round of investments
Life Science Angels' recent investments
Life Science Angels has not made any investment in 2026 so far.Here are the most recent investments by Life Science Angels:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Oct 16, 2025 | United States | Seed | 2325 | [+1] | |
Apr 08, 2025 | United States | Series A | 8501 | ||
Dec 03, 2024 | United States | Seed | 4072 | [+2] | |
2024 | Canada | Series A | 8395 | [+3] | |
Apr 22, 2024 | United States | Seed | 6224 | [+3] |
IPOs and Publicly Listed companies in Life Science Angels' Portfolio
2 of Life Science Angels' portfolio companies have become public. Owlet got listed on the New York Stock Exchange (NYSE), OTC Markets (OTCMKTS), in Nov 2020 and Vaxart got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).Here are Life Science Angels' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Nov 05, 2020 | Apr 22, 2014 | Seed | 3926 | |
Feb 12, 2018 | Nov 15, 2007 | Series A | 1287 |
Acquired companies in Life Science Angels' Portfolio
9 companies from Life Science Angels' portfolio have been acquired. The most recent acquisition were Fluxion Biosciences in Aug 2023 by Cell Microsystems.Here are Life Science Angels' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 23, 2023 | Nov 13, 2007 | Series A | 6244 | |
Jul 29, 2022 | Mar 24, 2016 | Series B | 3682 | |
Jan 19, 2022 | Aug 28, 2006 | Series A | 6286 | |
Apr 28, 2021 | Sep 22, 2008 | Series A | 3277 | |
Aug 02, 2019 | Apr 2008 | Series B | 9832 |
Co-investors of Life Science Angels
Over the past 20 years, 242 investors have co-invested in Life Science Angels's portfolio companies. This includes funds and angels.
- Invested before Life Science Angels: HHS, National Science Foundation and 41 others have invested in rounds before Life Science Angels. There are 8 companies where HHS has invested before Life Science Angels and 3 companies where National Science Foundation has invested before Life Science Angels.
- Top Co-investors of Life Science Angels: 111 investors entered a company along with Life Science Angels. These include investors like Tech Coast Angels (7 companies).
- Invested after Life Science Angels: A total of 88 investors have invested in Life Science Angels's portfolio after their investments. Top Investors include HHS (4 companies) and NIH (2 companies).
Recent News related to Life Science Angels
•
ATDev Secures $3 Million Seed Investment to Scale Assistive Mobility EcosystemPR Newswire•Oct 16, 2025•ATDev, UpHonest Capital, Life Science Angels, MAI and 2 others
•
Journey secures $8M for EAP mental health platformMobiHealthNews•Jul 25, 2025•Journey, Cambrian Growth Partners, ManchesterStory Group, Canaan and 4 others
•
Nervonik Raises $13 Million In Series A Financing To Advance Next-generation Peripheral Nerve Stimulation For Chronic Pain Reliefintelligence360•Mar 17, 2025•Nervonik, Usventure, USVP, Foothill Ventures and 6 others
•
Nervonik Receives $13M Series AMassinvestor•Mar 05, 2025•Nervonik, SUVC, Foothill Ventures, Correlation Ventures and 6 others
•
TRIO Pharmaceuticals Completes $3.1 Million Financing Round to Advance Cancer Therapeutics PipelineBakersfield•Dec 03, 2024•Trio Pharmaceuticals, The MMRF, Myeloma Investment Fund, NuFund and 1 other
•
Pelvital Closes $5M in Expand Stress Urinary Incontinence TreatmentHIT Consultant•Apr 22, 2024•Flyte, Boomerang Ventures, Pier 70 Ventures, Life Science Angels and 2 others
•
Neurava raises over $2M to advance life-saving epilepsy monitoring devicePR Newswire•Apr 03, 2024•Neurava, Life Science Angels, Purdueinnovates, First Leaf Capital and 4 others
•
•
•
Virion Therapeutics Raises $4MCitybizlist•Sep 17, 2018•Virion Therapeutics, Robin Hood Ventures, Keiretsu Capital, Keiretsu Forum and 3 others
